This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

MarketVIEW: Staphylococcus Aureus Vaccines

NEW YORK, Feb. 18, 2013 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

MarketVIEW: Staphylococcus aureus vaccines

Gram-positive Staphylococcus aureus is an opportunistic pathogen and a major cause of patient morbidity and mortality, especially in "at risk" populations. The organism can cause a wide range of infections ranging from mild skin infections to life-threatening bloodstream infections and pneumonia.

Prophylatic vaccines could prevent S.aureus infections and become cost effective in achieving savings from expensive infection control interventions e.g. MRSA screening on admission. Although all major companies have now announced S.aureus vaccine programs, Pfizer (SA4Ag) are the most advanced now the Merck & Co (Intercell AG) candidate, V710 has been terminated. 

This MarketVIEW product gives a comprehensive vaccine value ($USD/volume (000s) forecast for all products within target nosocomial populations until 2030. The model includes LO/BASE/HI forecast scenarios so the user can visualize the commercial impact of differing targetting/competitive and pricing scenarios. This product is an essential component of any commercial opportunistic assessment focused on nosocomial vaccines.

THIS PRODUCT IS A SUMMARY PRESENTATION + MODEL Contents – Summary presentation (MS PowerPoint based)Author's noteContentsExecutive SummaryCommercial model – key outputsTotal global available market ($000s all scenarios), pricing level 1Total global available market ($000s all scenarios), pricing level 2Total global available market ($000s all scenarios), pricing level 3Total predicted demand (doses 000s all scenarios)Total available volume per vaccine segment, US – 2025Model forecast comparisons: March 2010 v current ( April 2012) – volume/valueModel forecast comparisons: March 2010 v current ( April 2012) – per segmentCompany revenue summaryModelling commercial potentialThe role of S.aureus vaccineCharacteristics of the ideal S.aureus vaccineS.aureus vaccine: target product profile (minimum)S.aureus vaccine: target product profile (ideal)Target populations: vaccination strategiesVaccine target populations: overviewVaccine target populations: scenario definitionMarkets included in modelCommercial model assumptions: generalCommercial model assumptions: short-term riskCommercial model assumptions: chronic riskModel forecast assumptions: comparing March 2010 with current (April 2012)Notes on PricingS.aureus vaccines: R&D pipelineCompetitor landscape overviewS.aureus vaccine: estimated launch datesPfizer: SA4Ag – backgroundPfizer: SA4Ag – Phase I dataGSK: GSK2392103A/NabiOther vaccine candidatesMerck & Co/Intercell AG – V710Staphylococcus aureus: update on infection controlSituation overview: MRSA infection controlUS situationReview of latest epidemiologyAcute care hospitals: USAcute care hospitals: pan-EuropeanAcute care hospitals: UKAcute care hospitals: GermanyAcute care hospitals: FranceEurope: methicillin-resistance disease trendsMRSA: colonization ratesBackup material: methodologyMethodology: general comments – CABG, ESRD & LTCFsMethodology: general comments – ICU/electiveMethodology: general comments – diabeticsBibliographyDisclaimerAbout VacZine AnalyticsPAGES: 80 MS PowerPoint slides, fully referenced/sourced. Available in .pdf formContents – Vaccine demand model (MS Excel-based)Title sheetTOTAL CHARTS – forecast to 2030CHARTS VALUE – pricing level 1CHARTS VALUE – pricing level 2CHARTS VALUE – pricing level 3CHARTS VOLUME – HIGHVALUE SUMMARY – pricing level 1VALUE SUMMARY – pricing level 2VALUE SUMMARY – pricing level 3Competitor summary (Base scenario)US (all scenarios LO/BASE/HIGH)CanadaUKGermanyFranceSpainItalyAustraliaJapanCountry target populations – forecast to 2030Source materialLTCFsCABGOrthopaedicESRDHospital admissionsElective admissionsDiabetesUS segmentsBack pageAbout VacZine AnalyticsDisclaimerWORKSHEETS: ~65

To order this report:: MarketVIEW: Staphylococcus aureus vaccines

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.02 0.00%
FB $104.07 0.00%
GOOG $683.57 0.00%
TSLA $162.60 0.00%
YHOO $27.97 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs